Analyst Profile

Followed by 46 followers
.
Chris Howerton

Chris Howerton

Jefferies
Wall Street Analyst
#7,708 out of 8,160 Wall Street Analysts
#23,157 out of 24,427 experts

Success Rate

38%
72 out of 188 transactions made a profit

Average Return

-7.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Chris Howerton's trades since 2015 and holding each position for 1 Year would result in 38.30% of your transactions generating a profit, with an average return of -7.8% per rating.

Stock Rating Distribution

280Ratings
78.21% Buy
20.71% Hold
1.07% Sell
Distribution of Chris Howerton's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
TG Therapeutics
(TGTX)
Rating:Buy
Date:Feb 06, 2019 - Feb 06, 2020
Return:+282.30%
The most profitable rating made by Chris Howerton

Chris Howerton's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Affimed
Oct 15, 2015
Hold
Reiterated
$7.00
(243.14% Upside)
3Ratings
0.00%
Altamira Therapeutics
Jul 12, 2016
Buy
Reiterated
$8.00
(36.16% Upside)
4Ratings
0%
-80.18%
LadRx
Jul 29, 2016
Hold
Reiterated
$0.75
(305.62% Upside)
8Ratings
0.00%
Anthera Pharmaceuticals
Aug 24, 2016
Buy
Reiterated
$45.00
(44999900.00% Upside)
5Ratings
0%
-89.13%
Salarius Pharmaceuticals
Aug 24, 2016
Buy
Reiterated
$25.00
(1266.12% Upside)
11Ratings
0%
-60.50%
Atara Biotherapeutics
Aug 24, 2016
Buy
Reiterated
$25.00
(468.18% Upside)
15Ratings
11%
-24.39%
Spectrum Pharmaceuticals
Nov 09, 2016
Hold
Reiterated
$6.00
(1170.11% Upside)
10Ratings
0.00%
Minerva Neurosciences
Jan 12, 2017
Buy
Reiterated
$17.00
(373.54% Upside)
9Ratings
17%
-27.48%
Synlogic
Apr 30, 2019
Buy
Initiated
$18.00
(2507.94% Upside)
1Ratings
0%
-75.70%
Milestone Pharmaceuticals
Jul 24, 2020
Buy
Upgraded
$15.00
(208.64% Upside)
3Ratings
0%
-62.35%
List of latest recommendations made by Chris Howerton. Click to expand and see Chris Howerton's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >